Sonnet BioTherapeutics Receives Notice Of Allowance For U.S. Patent Covering Composition Of Matter Of Specific Amino Acid Substitutions Of Its IL-18 Binding Protein Resistant Variant Protein
Express News | Sonnet Biotherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of Its Il-18 Binding Protein Resistant Variant Protein
Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for '25" Conference
Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
Express News | Sonnet Biotherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform Is Available for Drug Discovery Partnerships With Potential for Producing Multiple Pipeline Drug Candidates
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
Sonnet BioTherapeutic | 10-Q: Q1 2025 Earnings Report
Sonnet BioTherapeutics Reports Wider Q1 Net Loss, CFO Transition
Express News | Sonnet Biotherapeutics Appoints Stephen Mcandrew, Ph.d. as Chief Business Officer
Press Release: Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer
Sonnet BioTherapeutics Q1 EPS $(1.56) Misses $(1.39) Estimate
Express News | Sonnet BioTherapeutics CFO Resigns Effective Feb. 21, 2025; Co Names Donald Griffith As Successor
Sonnet BioTherapeutic | 8-K: Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
Sonnet BioTherapeutics Reports Positive Interim Results From Phase 1 SB101 Trial of SON-1010 and Advances Clinical Programs
Sonnet BioTherapeutics Jay Cross Submitted His Resignation as Chief Fincl Officer, Effective Feb 21 >SONN
Press Release: Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
Express News | Sonnet Biotherapeutics Further Expands Global Intellectual Property Portfolio With Issuance of EU Patent for Fhab® Platform Technology
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Sonnet BioTherapeutics Has Been Granted European Patent Number EP3583125 Titled "ALBUMIN BINDING DOMAIN FUSION PROTEINS (FOR THE TREATMENT OF CANCER)".